Search

Amy B Dounay

from Colorado Springs, CO
Age ~50
Get Report
Also known as:
Amy Beth Dounay, Amy B Atwood
Phone and address:
5725 Astoria Way, Colorado Springs, CO 80919
(719) 418-3621
Connected to:
Dan C Doung, 74George V Dounhoo, 61Anoiel Douniadeh, 35Catherine A Dounies, 103Dimitrios Dounis, 57Grace Dounis, 37Vanessa M Dounis, 37Paul Dounn, 77Gerald Dounson, 58Jesse N Doup, 35

Amy Dounay Phones & Addresses

  • 5725 Astoria Way, Colorado Spgs, CO 80919 (719) 418-3621
  • Colorado Springs, CO
  • Minneapolis, MN
  • 13 Cranwood Rd, Ledyard, CT 06339 (860) 245-5590
  • 620 Hidden Valley Club Dr, Ann Arbor, MI 48104 (734) 222-8478
  • 2805 Yost Blvd, Ann Arbor, MI 48104
  • Irvine, CA
  • Englewood, CO
  • 5725 Astoria Way, Colorado Springs, CO 80919 (860) 245-5590

Work

Company: Colorado college Feb 2018 Position: Associate professor

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Minnesota 1996 to 2001 Specialities: Chemistry

Skills

Neuroscience • Analytical Chemistry • Cheminformatics

Industries

Pharmaceuticals

Resumes

Resumes

Amy Dounay Photo 1

Associate Professor

View page
Location:
Colorado Springs, CO
Industry:
Pharmaceuticals
Work:
Colorado College
Associate Professor
Colorado College
Assistant Professor, Department of Chemistry
Pfizer Aug 2010 - Aug 2012
Senior Principal Scientist
Pfizer Apr 2004 - Jun 2007
Principal Scientist
Uc Irvine 2001 - 2004
Postdoctoral Fellow
Education:
University of Minnesota 1996 - 2001
Doctorates, Doctor of Philosophy, Chemistry Colorado College 1992 - 1996
Bachelors, Bachelor of Arts, Chemistry
Skills:
Neuroscience
Analytical Chemistry
Cheminformatics

Publications

Us Patents

Kat Ii Inhibitors

View page
US Patent:
8487104, Jul 16, 2013
Filed:
Nov 30, 2011
Appl. No.:
13/307140
Inventors:
Amy B Dounay - Ledyard CT, US
Christopher J Helal - Mystic CT, US
Jamison B Tuttle - Westbrook CT, US
Patrick R Verhoest - Old Lyme CT, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
C07D 215/58
US Classification:
546155, 514312
Abstract:
The present invention relates to compounds 3-amino-1-hydroxy-2-oxo-1,2,3, 4-tetrahydroquinoline-7-carbonitrile, 3-amino-1-hydroxy-7-(2-methoxyethoxy)-3,4-dihydroquinolin-2(1H)-one, and 3-amino-1-hydroxy-7-[(1S)-2-methoxy-1-methylethoxy]-3,4-dihydroquinolin-2(1H)-one, including racemic mixtures and resolved enantiomers thereof, to pharmaceutically acceptable salts thereof, and to the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.

Kat Ii Inhibitors

View page
US Patent:
8598200, Dec 3, 2013
Filed:
Nov 30, 2011
Appl. No.:
13/307636
Inventors:
Amy B Dounay - Ledyard CT, US
Laura McAllister - Pawcatuck CT, US
Vinod D Parikh - Mystic CT, US
Suobao Rong - Groton CT, US
Patrick R Verhoest - Old Lyme CT, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
A01N 43/42
A61K 31/44
A01N 43/40
A61K 31/445
A01N 43/56
A61K 31/415
US Classification:
514303, 514330, 514407, 514322
Abstract:
Compounds of Formula I:.

Bicyclic And Tricyclic Compounds As Kat Ii Inhibitors

View page
US Patent:
20100324043, Dec 23, 2010
Filed:
Jun 16, 2010
Appl. No.:
12/816612
Inventors:
Michelle M. Claffey - Stonington CT, US
Amy B. Dounay - Ledyard CT, US
Matthew M. Hayward - Old Lyme CT, US
Suobao Rong - Groton CT, US
Patrick R. Verhoest - Old Lyme CT, US
Jamison B. Tuttle - Westbrook CT, US
Xinmin Gan - Groton CT, US
International Classification:
A61K 31/5377
C07D 471/04
A61K 31/4375
C07D 215/58
A61K 31/4704
C07D 221/10
A61K 31/473
C07D 413/10
C07D 491/048
A61K 31/4741
C07D 401/12
C07D 401/10
C07D 405/10
A61K 31/506
A61K 31/501
C07D 413/12
A61K 31/517
C07D 487/04
A61K 31/519
C07D 473/30
A61K 31/52
A61P 25/00
A61P 25/18
A61P 25/16
A61P 9/10
A61P 25/30
A61P 25/28
A61P 25/24
A61P 27/02
A61P 29/00
A61P 35/00
A61P 13/00
US Classification:
5142352, 546122, 514300, 546155, 514312, 546110, 514290, 544128, 546 89, 514291, 544331, 514275, 544238, 51425204, 544319, 514269, 544284, 51426621, 544281, 51425931, 544280, 5142651, 544276, 51426322, 544263, 5142621
Abstract:
Compounds of Formula X:wherein A, X, Y, Z, R, R, and Rare as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.

Novel Phenyl Imidazoles And Phenyl Triazoles As Gamma-Secretase Modulators

View page
US Patent:
20120053165, Mar 1, 2012
Filed:
Mar 2, 2010
Appl. No.:
13/203988
Inventors:
Martin Patrick Allen - Groton CT, US
Christopher William Am Ende - Groton CT, US
Michael Aaron Brodney - Groton CT, US
Amy Beth Dounay - Groton CT, US
Douglas Scott Johnson - Groton CT, US
Martin Youngjin Pettersson - Groton CT, US
Jacob Bradley Schwartz - Groton CT, US
Tuan Phong Tran - Groton CT, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
A61K 31/4178
A61K 31/4164
C07D 413/12
A61K 31/422
A61K 31/4245
C07D 249/08
A61K 31/4196
C07D 405/12
C07D 409/12
C07D 403/12
C07D 417/12
A61K 31/427
A61K 31/423
C07D 403/10
C07D 401/10
A61K 31/454
A61K 31/5377
A61K 31/437
A61P 25/00
A61P 25/18
C07D 233/61
US Classification:
51421018, 5483435, 514399, 548247, 514378, 548143, 514364, 5482694, 514383, 5483111, 514397, 5483114, 5483124, 5483147, 5483121, 548204, 514365, 548241, 514379, 546210, 514326, 544139, 5142358, 514292
Abstract:
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Heteroaromatic Compounds And Their Use As Dopamine D1 Ligands

View page
US Patent:
20210300899, Sep 30, 2021
Filed:
Mar 17, 2021
Appl. No.:
17/204095
Inventors:
- New York NY, US
Jennifer Elizabeth Davoren - Cambridge MA, US
Amy Beth Dounay - Colorado Springs CO, US
Ivan Viktorovich Efremov - Brookline MA, US
David Lawrence Firman Gray - Groton MA, US
Michael Eric Green - Boston MA, US
Jaclyn Louise Henderson - Cambridge MA, US
Chewah Lee - Wallingford CT, US
Scot Richard Mente - Arlington MA, US
Steven Victor O'Neil - East Lyme CT, US
Bruce Nelsen Rogers - Belmont MA, US
Lei Zhang - Auburndale MA, US
International Classification:
C07D 401/14
C07D 401/12
C07D 405/14
A61P 25/28
A61P 25/18
A61K 31/444
A61K 31/506
A61K 31/501
A61K 31/513
C07D 403/12
Abstract:
The present invention provides, in part, compounds of Formula I:and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, Tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, SLE, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.

Heteroaromatic Compounds And Their Use As Dopamine D1 Ligands

View page
US Patent:
20200283407, Sep 10, 2020
Filed:
May 21, 2020
Appl. No.:
16/880632
Inventors:
- New York NY, US
Jennifer Elizabeth Davoren - Cambridge MA, US
Amy Beth Dounay - Colorado Springs CO, US
Ivan Viktorovich Efremov - Brookline MA, US
David Lawrence Firman Gray - Groton MA, US
Michael Eric Green - Boston MA, US
Jaclyn Louise Henderson - Cambridge MA, US
Chewah Lee - Wallingford CT, US
Scot Richard Mente - Arlington MA, US
Steven Victor O'Neil - East Lyme CT, US
Bruce Nelsen Rogers - Belmont MA, US
Lei Zhang - Auburndale MA, US
International Classification:
C07D 401/14
C07D 401/12
C07D 405/14
A61P 25/28
A61P 25/18
A61K 31/444
A61K 31/506
A61K 31/501
A61K 31/513
C07D 403/12
Abstract:
The present invention provides, in part, compounds of Formula I:and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), Parkinson's disease and chronic apathy.

Heteroaromatic Compounds And Their Use As Dopamine D1 Ligands

View page
US Patent:
20190367485, Dec 5, 2019
Filed:
Aug 13, 2019
Appl. No.:
16/539865
Inventors:
- New York NY, US
Jennifer Elizabeth Davoren - Cambridge MA, US
Amy Beth Dounay - Colorado Springs CO, US
Ivan Viktorovich Efremov - Brookline MA, US
David Lawrence Firman Gray - Groton MA, US
Michael Eric Green - Boston MA, US
Jaclyn Louise Henderson - Cambridge MA, US
Chewah Lee - Wallingford CT, US
Scot Richard Mente - Arlington MA, US
Steven Victor O'Neil - East Lyme CT, US
Bruce Nelsen Rogers - Belmont MA, US
Lei Zhang - Auburndale MA, US
International Classification:
C07D 401/14
C07D 403/12
A61K 31/513
A61K 31/501
A61K 31/506
A61K 31/444
C07D 405/14
C07D 401/12
Abstract:
The present invention provides, in part, compounds of Formula I:and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.

Heteroaromatic Compounds And Their Use As Dopamine D1 Ligands

View page
US Patent:
20190002439, Jan 3, 2019
Filed:
Sep 6, 2018
Appl. No.:
16/123072
Inventors:
- New York NY, US
JENNIFER ELIZABETH DAVOREN - CAMBRIDGE MA, US
AMY BETH DOUNAY - COLORADO SPRINGS CO, US
IVAN VIKTOROVICH EFREMOV - BROOKLINE MA, US
DAVID LAWRENCE FIRMAN GRAY - GROTON MA, US
MICHAEL ERIC GREEN - BOSTON MA, US
JACLYN LOUISE HENDERSON - CAMBRIDGE MA, US
CHEWAH LEE - WALLINGFORD CT, US
SCOT RICHARD MENTE - ARLINGTON MA, US
STEVEN VICTOR O'NEIL - EAST LYME CT, US
BRUCE NELSEN ROGERS - BELMONT MA, US
LEI ZHANG - AUBURNDALE MA, US
Assignee:
PFIZER INC. - New York NY
International Classification:
C07D 401/14
A61K 31/513
A61K 31/501
A61K 31/506
C07D 405/14
C07D 403/12
C07D 401/12
A61K 31/444
Abstract:
The present invention provides, in part, compounds of Formula I:and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.
Control profile
Amy B Dounay from Colorado Springs, CO, age ~50 Get Report